Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Inside information: Citycon Oyj explores the conditions to carry out a directed share issue of up to 11.9 million new shares and plans other measures to further strengthen its balances sheet





HELSINKI, Feb. 22, 2024 /PRNewswire/ — Citycon Oyj (“Citycon” or the “Company“) explores the conditions to carry out a directed share issue of up to 11.9 million new shares in the Company (the “Shares“), corresponding to up to approximately 6.9 per cent of all shares in the Company prior to the directed share issue, by means of an accelerated bookbuilding process (the “Placing“). The Placing would be directed only to eligible Finnish and international institutional and other qualified investors.

The Placing would be carried out based on the authorisation granted to the Board of Directors by the Company’s Annual General Meeting held on 21 March 2023. The subscription price and the total number of Shares to be offered in the Placing would be determined based on offers received in the Placing. The Company has retained Deutsche Bank Aktiengesellschaft (“Deutsche Bank“) and Skandinaviska Enskilda Banken AB (publ) Helsinki branch (“SEB“) as Joint Bookrunners in connection with the Placing.

The Placing will be launched immediately following the publication of this stock exchange release and is expected to end no later than at 9:00 a.m. EET on 23 February 2024 (the “Placing Period“). The bookbuilding may, however, be closed at any time during the Placing Period. After the close of the Placing, the Board of Directors of the Company will make the decision on the Placing, including acceptance of the received offers, the number of Shares to be issued and the subscription price per Share. The final number and subscription price will be published by way of a stock exchange release after the close of the Placing.

The net proceeds from the Placing are intended to be used to strengthen the Company’s balance sheet by repaying the Company’s outstanding debt, and thus, improving its capital structure in the current market environment, while doing so in a rapid and cost-effective manner that, in the assessment of the Company, would otherwise not be available in the current market conditions. The capital structure and balance sheet strengthening would also support the Company in maintaining its investment grade credit rating. There are, therefore, weighty financial reasons for the Company to deviate from shareholders’ pre-emptive subscription rights.

The Company aims to continue assessing its balance sheet position and may undertake other ordinary course capital markets transactions to optimise its capital structure in the near future, including refinancing by issuing a new bond and repurchasing its bonds maturing in 2024, subject to market conditions.

In the Board of Directors’ assessment, the subscription price per Share is expected to be in accordance with the prevailing market conditions since it would be determined through an accelerated bookbuilding procedure.

G City Ltd, who currently owns, together with its wholly-owned subsidiary Gazit Europe Netherlands, 50.91 per cent of the total shares and votes in the Company, has committed to subscribe 3.7 million Shares in the Placing. Pursuant to an approval by the FIN-FSA relating to a mandatory tender offer exemption, G City Ltd’s aggregate shareholding must be below 50 per cent of the total shares and votes in the Company after the completion of the Placing. Ilmarinen Mutual Pension Insurance Company is supportive of, and intends to participate in, the Placing.

In connection with the Placing, the Company has agreed to enter into a lock-up undertaking, according to which it will, subject to certain customary exceptions and/or waiver by the Joint Bookrunners, undertake not to issue or sell shares in the Company during a period of 90 days after the completion of the Placing.

Subject to the completion of the Placing, the Shares would be registered with the Finnish Trade Register on or about 23 February 2024. The Shares are expected to be ready for delivery to the investors against payment through Euroclear Finland Ltd on or about 27 February 2024. Trading in the Shares is expected to commence on the official list of Nasdaq Helsinki Ltd on or about 27 February 2024. The Shares would rank pari passu in all respects with the existing shares of the Company once they have been entered in the Finnish Trade Register.

Deutsche Bank and SEB act as Joint Bookrunners of the Placing. Hannes Snellman Attorneys Ltd and Milbank LLP are acting as the legal advisers to the Company and Roschier, Attorneys Ltd. is acting as the legal adviser to the Joint Bookrunners.

Citycon Oyj
Board of Directors

For further information, please contact:  
Sakari Järvelä
Chief Financial Officer
Tel. +358 50 387 8180
[email protected] 

Citycon is a leading owner, manager and developer of mixed-use real estate featuring modern, necessity-based retail with residential, office and municipal service spaces that enhance the communities in which they operate. Citycon is committed to sustainable property management in the Nordic region with assets that total approximately EUR 4.0 billion. Our centres are located in urban hubs in the heart of vibrant communities with direct connections to public transport and anchored by grocery, healthcare and other services that cater to the everyday needs of customers.

Citycon has investment-grade credit rating from Standard & Poor’s (BBB-). Citycon’s shares are listed on Nasdaq Helsinki Ltd. 

Forward-Looking Statements

This release contains forward-looking statements, including, without limitation, statements regarding Citycon’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this release, including, without limitation, any related to Citycon’s business, operations, supply chain, strategy, goals and anticipated timelines and competition from other companies. Citycon cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Citycon disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this release represent Citycon’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Important notice

The information contained herein shall not constitute an offer to sell or the solicitation of any offer to buy or subscribe for, nor shall there be any sale of the securities referred to herein in any jurisdiction.

The information contained herein may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, South Africa, Singapore, New Zealand or Japan or in any other jurisdiction in which such announcement, publication or distribution would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Finnish law. This press release does not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. There is no intention to register any portion of the offering in the United States or to conduct a public offering of the securities in the United States. Any sale of the issued Shares in the United States will be made solely to “qualified institutional buyers” as defined in rule 144A in reliance on an exemption from the registration requirements of the U.S. Securities Act.

In any EEA Member State, this announcement is only addressed to and is only directed at qualified investors in that Member State within the meaning of Regulation (EU) 2017/1129 (“Prospectus Regulation”) (“Relevant Persons”). Persons who are not Relevant Persons should not take any action on the basis of this announcement and should not act or rely on it.

Deutsche Bank Aktiengesellschaft and Skandinaviska Enskilda Banken AB (publ) Helsinki branch act only for and on behalf of the Company in connection of the Placing. Deutsche Bank Aktiengesellschaft and Skandinaviska Enskilda Banken AB (publ) Helsinki branch do not hold any other party as their client or cannot be held accountable to advise or indemnify other parties than the Company with regards to the Placing or other matters referred here to.

View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading